Actavis Elizabeth, LLC, Petiioner v. Gladys Mensing.

Questions presented

SCOTUS records, cert granted 10 Dec 2010

The Drug Price Competition and Patent Term Restoration Act (the "Hatch- Waxman Amendments" to the Food, Drug and Cosmetic Act (FDCA)) and its implementing regulations require a generic drug manufacturer to maintain the labeling for a generic the "same as" the labeling for the "brand" or "listed" drug that is its bioequivalent. See 21 U.S.C. 9 §355(j)(2)(A)(iv-v); 21 C.F.R. § 314.94(a)(8). The question presented is whether the Eighth Circuit Court of Appeals misinterpreted that requirement and the doctrine of conflict preemption when it concluded that generic drug manufacturers could be held liable under state law for failing to strengthen the warnings in the labeling for the generic drug.

Opinion summary

Etalia.ai summary of the majority opinion

The case involves a legal dispute where Gladys Mensing sued Actavis Elizabeth, LLC over injuries allegedly caused by the generic drug metoclopramide. Mensing claimed that the manufacturer failed to provide adequate warnings about the risks associated with long-term use of the medication. The central issue was whether federal law preempts state-law claims against generic drug manufacturers for failure to warn consumers when they are required to match brand-name labeling approved by the FDA. The Supreme Court ruled in favor of Actavis, holding that federal regulations requiring generics to have identical labels as their brand-name counterparts preempted state laws imposing additional duties on these manufacturers.